Rocket Pharmaceuticals to Host Conference Call to Reveal First AAV Gene Therapy Program
Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces that management will host a conference call on Monday, November 26th , 2018, at 8:30 a.m. ET to reveal their first adeno-associated viral vector (AAV) gene therapy program.
To participate in the conference call, please dial (866) 679-4266 in the U.S. or (409) 217-8318 outside of the U.S. five minutes prior to the start of the call and provide the Conference ID of 5673299 or access the listen-only webcast by visiting the Company’s website at www.rocketpharma.com. An archive of the webcast will be available on the Company’s website for thirty days.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, devastating diseases. Rocket’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. Rocket's lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. Preclinical studies of additional bone marrow-derived disorders are ongoing and target Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). Rocket is also developing an AAV-based gene therapy program for an undisclosed rare pediatric disease. For more information about Rocket, please visit www.rocketpharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181125005027/en/